{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:27:54Z","timestamp":1793604474115,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170595"],"award-info":[{"award-number":["82170595"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970070"],"award-info":[{"award-number":["81970070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000546"],"award-info":[{"award-number":["82000546"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012239","name":"Hubei Technological Innovation Special Fund","doi-asserted-by":"publisher","award":["20204201117303072238"],"award-info":[{"award-number":["20204201117303072238"]}],"id":[{"id":"10.13039\/501100012239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-alcoholic fatty liver (NAFLD) and its related metabolic syndrome have become major threats to human health, but there is still a need for effective and safe drugs to treat these conditions. Here we aimed to identify potential drug candidates for NAFLD and the underlying molecular mechanisms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A drug repositioning strategy was used to screen an FDA-approved drug library with approximately 3000 compounds in an in vitro hepatocyte model of lipid accumulation, with honokiol identified as an effective anti-NAFLD candidate. We systematically examined the therapeutic effect of honokiol in NAFLD and metabolic syndrome in multiple in vitro and in vivo models. Transcriptomic examination and biotin-streptavidin binding assays were used to explore the underlying molecular mechanisms, confirmed by rescue experiments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Honokiol significantly inhibited metabolic syndrome and NAFLD progression as evidenced by improved hepatic steatosis, liver fibrosis, adipose inflammation, and insulin resistance. Mechanistically, the beneficial effects of honokiol were largely through AMPK activation. Rather than acting on the classical upstream regulators of AMPK, honokiol directly bound to the AMPK\u03b31 subunit to robustly activate AMPK signaling. Mutation of honokiol-binding sites of AMPK\u03b31 largely abolished the protective capacity of honokiol against NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings clearly demonstrate the beneficial effects of honokiol in multiple models and reveal a previously unappreciated signaling mechanism of honokiol in NAFLD and metabolic syndrome. This study also provides new insights into metabolic disease treatment by targeting AMPK\u03b31 subunit-mediated signaling activation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13020-023-00729-5","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T21:17:44Z","timestamp":1679087864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome"],"prefix":"10.1186","volume":"18","author":[{"given":"Ruifeng","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"issue":"10290","key":"729_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"5","key":"729_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik JM, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72(5):1605\u201316.","journal-title":"Hepatology"},{"issue":"4","key":"729_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, et al. Unexpected rapid increase in the Burden of NAFLD in China From 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70(4):1119\u201333.","journal-title":"Hepatology"},{"issue":"4","key":"729_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904.","journal-title":"J Hepatol"},{"issue":"1","key":"729_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123\u201333.","journal-title":"Hepatology"},{"issue":"5","key":"729_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","volume":"126","author":"J Cai","year":"2020","unstructured":"Cai J, et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020;126(5):679\u2013704.","journal-title":"Circ Res"},{"issue":"11","key":"729_CR7","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/CIRCRESAHA.121.319059","volume":"128","author":"Z Chen","year":"2021","unstructured":"Chen Z, et al. Nonalcoholic fatty liver disease: an emerging driver of cardiac arrhythmia. Circ Res. 2021;128(11):1747\u201365.","journal-title":"Circ Res"},{"key":"729_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-022-00547-x","author":"GR Steinberg","year":"2022","unstructured":"Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2022. https:\/\/doi.org\/10.1038\/s41580-022-00547-x.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"729_CR9","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1016\/j.molcel.2021.08.015","volume":"81","author":"E Trefts","year":"2021","unstructured":"Trefts E, Shaw RJ. AMPK: restoring metabolic homeostasis over space and time. Mol Cell. 2021;81(18):3677\u201390.","journal-title":"Mol Cell"},{"issue":"7","key":"729_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","volume":"18","author":"GR Steinberg","year":"2019","unstructured":"Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov. 2019;18(7):527\u201351.","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"729_CR11","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1093\/jxb\/erw211","volume":"67","author":"V Roustan","year":"2016","unstructured":"Roustan V, et al. An evolutionary perspective of AMPK\u2013TOR signaling in the three domains of life. J Exp Bot. 2016;67(13):3897\u2013907.","journal-title":"J Exp Bot"},{"issue":"13","key":"729_CR12","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1016\/j.celrep.2017.03.011","volume":"18","author":"A Woods","year":"2017","unstructured":"Woods A, et al. Liver-specific activation of ampk prevents steatosis on a high-fructose diet. Cell Rep. 2017;18(13):3043\u201351.","journal-title":"Cell Rep"},{"key":"729_CR13","unstructured":"Selleckchem.com. FDA-approved Drug Library."},{"issue":"2","key":"729_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pharmthera.2011.01.010","volume":"130","author":"YJ Lee","year":"2011","unstructured":"Lee YJ, et al. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 2011;130(2):157\u201376.","journal-title":"Pharmacol Ther"},{"key":"729_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.biomaterials.2015.02.091","volume":"53","author":"JH Cho","year":"2015","unstructured":"Cho JH, et al. Multifunctional effects of honokiol as an anti-inflammatory and anti-cancer drug in human oral squamous cancer cells and xenograft. Biomaterials. 2015;53:274\u201384.","journal-title":"Biomaterials"},{"key":"729_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fphar.2017.00216","volume":"8","author":"H Xiang","year":"2017","unstructured":"Xiang H, et al. Chinese herbal medicines attenuate acute pancreatitis: pharmacological activities and mechanisms. Front Pharmacol. 2017;8:216.","journal-title":"Front Pharmacol"},{"key":"729_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2022.2120541","author":"F Khatoon","year":"2022","unstructured":"Khatoon F, et al. Pharmacological features, health benefits and clinical implications of honokiol. J Biomol Struct Dyn. 2022. https:\/\/doi.org\/10.1080\/07391102.2022.2120541.","journal-title":"J Biomol Struct Dyn"},{"issue":"9","key":"729_CR18","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.3390\/molecules15096452","volume":"15","author":"JL Shen","year":"2010","unstructured":"Shen JL, et al. Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules. 2010;15(9):6452\u201365.","journal-title":"Molecules"},{"key":"729_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.fct.2017.10.033","volume":"119","author":"RB Feng","year":"2018","unstructured":"Feng RB, et al. Gallic acid, a natural polyphenol, protects against tert-butyl hydroperoxide- induced hepatotoxicity by activating ERK-Nrf2-Keap1-mediated antioxidative response. Food Chem Toxicol. 2018;119:479\u201388.","journal-title":"Food Chem Toxicol"},{"issue":"16","key":"729_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1055\/a-0642-1966","volume":"84","author":"A Sarrica","year":"2018","unstructured":"Sarrica A, et al. Safety and toxicology of magnolol and honokiol. Planta Med. 2018;84(16):1151\u201364.","journal-title":"Planta Med"},{"issue":"2","key":"729_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.taap.2015.02.020","volume":"284","author":"MS Seo","year":"2015","unstructured":"Seo MS, et al. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes. Toxicol Appl Pharmacol. 2015;284(2):113\u201324.","journal-title":"Toxicol Appl Pharmacol"},{"key":"729_CR22","doi-asserted-by":"publisher","first-page":"2313641","DOI":"10.1155\/2020\/2313641","volume":"2020","author":"T Zhai","year":"2020","unstructured":"Zhai T, et al. Honokiol alleviates methionine-choline deficient diet-induced hepatic steatosis and oxidative stress in C57BL\/6 Mice by regulating CFLAR-JNK pathway. Oxid Med Cell Longev. 2020;2020:2313641.","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"729_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/jgh.13853","volume":"33","author":"X Zhong","year":"2018","unstructured":"Zhong X, Liu H. Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor gamma. J Gastroenterol Hepatol. 2018;33(2):524\u201332.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"729_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13020-021-00528-w","volume":"16","author":"J Liu","year":"2021","unstructured":"Liu J, et al. Honokiol attenuates lipotoxicity in hepatocytes via activating SIRT3-AMPK mediated lipophagy. Chin Med. 2021;16(1):115.","journal-title":"Chin Med"},{"issue":"5","key":"729_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","volume":"31","author":"C Jian","year":"2020","unstructured":"Jian C, et al. Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis. Cell Metab. 2020;31(5):892-908 e11.","journal-title":"Cell Metab"},{"issue":"7665","key":"729_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature23275","volume":"548","author":"CS Zhang","year":"2017","unstructured":"Zhang CS, et al. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. Nature. 2017;548(7665):112\u20136.","journal-title":"Nature"},{"issue":"624","key":"729_CR27","doi-asserted-by":"publisher","first-page":"eabg8116","DOI":"10.1126\/scitranslmed.abg8116","volume":"13","author":"XJ Zhang","year":"2021","unstructured":"Zhang XJ, et al. A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Sci Transl Med. 2021;13(624):eabg8116.","journal-title":"Sci Transl Med"},{"issue":"6","key":"729_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321.","journal-title":"Hepatology"},{"issue":"5","key":"729_CR29","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/hep.30333","volume":"69","author":"G Farrell","year":"2019","unstructured":"Farrell G, et al. Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis. Hepatology. 2019;69(5):2241\u201357.","journal-title":"Hepatology"},{"key":"729_CR30","doi-asserted-by":"publisher","unstructured":"Liu, H, et al., The glucotoxicity protecting effect of honokiol in human hepatocytes via directly activating AMPK. Frontiers\nin Nutrition. 9:1043009. https:\/\/doi.org\/10.3389\/fnut.2022.1043009.","DOI":"10.3389\/fnut.2022.1043009"},{"key":"729_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153647","volume":"90","author":"A Rauf","year":"2021","unstructured":"Rauf A, et al. Honokiol: a review of its pharmacological potential and therapeutic insights. Phytomedicine. 2021;90: 153647.","journal-title":"Phytomedicine"},{"key":"729_CR32","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.3389\/fimmu.2019.02800","volume":"10","author":"Y Ding","year":"2019","unstructured":"Ding Y, et al. Honokiol ameliorates high-fat-diet-induced obesity of different sexes of mice by modulating the composition of the gut microbiota. Front Immunol. 2019;10:2800.","journal-title":"Front Immunol"},{"issue":"6","key":"729_CR33","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/ani11061493","volume":"11","author":"Y Ding","year":"2021","unstructured":"Ding Y, et al. Honokiol alleviates high-fat diet-induced obesity of mice by inhibiting adipogenesis and promoting white adipose tissue browning. Animals. 2021;11(6):1493.","journal-title":"Animals"},{"issue":"7","key":"729_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516\u201325.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"729_CR35","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"issue":"2","key":"729_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"729_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","volume":"31","author":"C Jian","year":"2020","unstructured":"Jian C, et al. Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis. Cell Metab. 2020;31(5):892-908.e11.","journal-title":"Cell Metab"},{"issue":"6478","key":"729_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1126\/science.aay0542","volume":"367","author":"P Zhao","year":"2020","unstructured":"Zhao P, et al. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science. 2020;367(6478):652\u201360.","journal-title":"Science"},{"issue":"6","key":"729_CR39","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1002\/hep.32066","volume":"74","author":"M Hu","year":"2021","unstructured":"Hu M, et al. Salidroside activates the AMP-activated protein kinase pathway to suppress nonalcoholic steatohepatitis in mice. Hepatology. 2021;74(6):3056\u201373.","journal-title":"Hepatology"},{"issue":"2","key":"729_CR40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31749","volume":"74","author":"T Lan","year":"2021","unstructured":"Lan T, et al. Cordycepin ameliorates nonalcoholic steatohepatitis by activation of the Amp-activated protein kinase signaling pathway. Hepatology. 2021;74(2):686\u2013703.","journal-title":"Hepatology"},{"issue":"6","key":"729_CR41","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/hep.31568","volume":"73","author":"Q Lin","year":"2021","unstructured":"Lin Q, et al. Activating adenosine monophosphate-activated protein kinase mediates fibroblast growth factor 1 protection from nonalcoholic fatty liver disease in mice. Hepatology. 2021;73(6):2206\u201322.","journal-title":"Hepatology"},{"issue":"6","key":"729_CR42","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1002\/hep.32068","volume":"74","author":"J Wan","year":"2021","unstructured":"Wan J, et al. Gastrodin improves nonalcoholic fatty liver disease through activation of the adenosine monophosphate-activated protein kinase signaling pathway. Hepatology. 2021;74(6):3074\u201390.","journal-title":"Hepatology"},{"issue":"1","key":"729_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cmet.2016.06.006","volume":"24","author":"EP Mottillo","year":"2016","unstructured":"Mottillo EP, et al. Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through brown and beige adipose tissue function. Cell Metab. 2016;24(1):118\u201329.","journal-title":"Cell Metab"},{"issue":"12","key":"729_CR44","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.bbalip.2015.08.007","volume":"1851","author":"X Deng","year":"2015","unstructured":"Deng X, et al. Docosahexaenoic acid inhibits proteolytic processing of sterol regulatory element-binding protein-1c (SREBP-1c) via activation of AMP-activated kinase. Biochim Biophys Acta. 2015;1851(12):1521\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"729_CR45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.tem.2022.08.004","volume":"33","author":"D Aguilar-Recarte","year":"2022","unstructured":"Aguilar-Recarte D, et al. Knocking on GDF15\u2019s door for the treatment of type 2 diabetes mellitus. Trends Endocrinol Metab. 2022;33(11):741\u201354.","journal-title":"Trends Endocrinol Metab"},{"issue":"7932","key":"729_CR46","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","volume":"610","author":"B Chen","year":"2022","unstructured":"Chen B, et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature. 2022;610(7932):562\u20138.","journal-title":"Nature"},{"key":"729_CR47","doi-asserted-by":"publisher","first-page":"687095","DOI":"10.3389\/fphar.2021.687095","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang Y, et al. Naringenin attenuates non-alcoholic fatty liver disease by enhancing energy expenditure and regulating autophagy via AMPK. Front Pharmacol. 2021;12:687095.","journal-title":"Front Pharmacol"},{"issue":"2","key":"729_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jcmm.12187","volume":"18","author":"C Wu","year":"2014","unstructured":"Wu C, et al. Cordycepin activates AMP-activated protein kinase (AMPK) via interaction with the \u03b31 subunit. J Cell Mol Med. 2014;18(2):293\u2013304.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"729_CR49","doi-asserted-by":"publisher","first-page":"10482","DOI":"10.1038\/s41598-020-67030-5","volume":"10","author":"H An","year":"2020","unstructured":"An H, et al. The importance of the AMPK gamma 1 subunit in metformin suppression of liver glucose production. Sci Rep. 2020;10(1):10482.","journal-title":"Sci Rep"},{"key":"729_CR50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","volume":"141","author":"X Zhu","year":"2019","unstructured":"Zhu X, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019;141:192\u2013204.","journal-title":"Free Radic Biol Med"},{"issue":"16","key":"729_CR51","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1111\/bph.14713","volume":"176","author":"Y Rao","year":"2019","unstructured":"Rao Y, et al. Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease\/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity. Br J Pharmacol. 2019;176(16):2877\u201393.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"729_CR52","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/hep.32404","volume":"76","author":"L Song","year":"2022","unstructured":"Song L, et al. FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis. Hepatology. 2022;76(4):1105\u201320.","journal-title":"Hepatology"},{"issue":"5","key":"729_CR53","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jhep.2013.12.012","volume":"60","author":"D Casta\u00f1o","year":"2014","unstructured":"Casta\u00f1o D, et al. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J Hepatol. 2014;60(5):1017\u201325.","journal-title":"J Hepatol"},{"issue":"6350","key":"729_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1126\/science.aah5582","volume":"357","author":"RW Myers","year":"2017","unstructured":"Myers RW, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science. 2017;357(6350):507\u201311.","journal-title":"Science"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-023-00729-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T22:02:20Z","timestamp":1679090540000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-023-00729-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["729"],"URL":"https:\/\/doi.org\/10.1186\/s13020-023-00729-5","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"11 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols for animal studies involving mice were approved by the Renmin Hospital of Wuhan University\u2019s Animal Care and Use Committee. The animals were treated humanely in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences and the National Institutes of Health. No human samples were studied in this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}